Ischemic stroke represents a neurological emergency caused by focal brain infarction resulting from arterial thrombosis, embolization, or severe hypoperfusion. Defined clinically by rapid-onset neurological deficits accompanied by imaging or pathologic evidence of central nervous system infarction, ischemic stroke ranks as the second leading cause of global mortality and third for combined death and disability among non-communicable diseases. Risk factors closely align with atherosclerosis contributors, including advanced age, smoking, hypertension, hypercholesterolemia, and diabetes mellitus. Symptom presentation varies depending on affected vascular territory, including anterior circulation, posterior circulation, and lacunar infarcts, with clinical manifestations evolving over hours as the ischemic penumbra's fate determines outcome severity.

Intracranial aneurysms, particularly wide-neck bifurcation lesions, present significant endovascular treatment challenges. Traditional coil embolization suffers from instability and high recurrence rates, while adjunctive techniques like balloon remodeling and stent-assisted coiling increase procedural complexity and require prolonged dual antiplatelet therapy, problematic in ruptured cases. Flow diversion, though effective for sidewall aneurysms, has limitations at bifurcation sites due to branch incorporation concerns and ongoing antiplatelet dependencies. Intrasaccular flow disruptors, exemplified by the Woven EndoBridge device, emerged to address these gaps by promoting aneurysm thrombosis while preserving parent vessel circulation without long-term antiplatelet requirements. Following FDA approval in 2018, the WEB-IT trial and subsequent prospective investigational device exemption trials established rigorous evidentiary standards through standardized endpoints and independent imaging review, advancing treatment options for this challenging patient population.

In the recent OPTION trial, IVT with TNK in the extended time window improved the rate of an excellent outcome for patients without large vessel occlusion who ...

This research article examines the clinical application of intra-arterial recombinant human TNK tissue-type plasminogen activator, a thrombolytic agent designed to dissolve blood clots through direct arterial administration. The study investigates the efficacy and safety profile of this treatment approach, which represents an advance in interventional thrombotic therapy. Published as a medRxiv preprint in June 2026, the work contributes to the growing body of evidence regarding novel drug delivery mechanisms for acute vascular conditions. The research is available in the public domain, allowing broad access for medical professionals and researchers interested in thrombolytic treatment innovations and their clinical outcomes.

By limiting protein adsorption, these coatings reduce platelet adhesion, leukocyte recruitment, and downstream thrombo-inflammatory activation [30,31].

The high incidence of in-stent restenosis (ISR) associated with bare-metal stents (BMS) undermines the viability of endovascular treatment as a treatment option for patients with severe symptomatic intracranial atherosclerotic stenosis (ICAS). The study aimed to evaluate whether durable fluoropolymer drug-eluting stents (DES) reduce the incidence of ISR compared with BMS in the treatment of severe ICAS.

This study shows preliminary evidence that there is significant variation in reported preferences for endovascular aneurysm occlusion. Some of this variation occurs between specialty types, but overall, there is a wide range of preferences when considering difficult-to-treat aneurysms. The findings underscore the dynamic nature of the field, where interventionalists demonstrate a willingness to incorporate new technologies into their practice regardless of when they received their training. Moreover, the study highlights ongoing debates surrounding the management of ruptured aneurysms. Importantly, respondents showed preferences for endovascular treatment modalities for clinical situations not yet studied in the literature, highlighting several areas meriting further investigation. Further studies are needed to see true variations in trends in clinical practice.

Despite major advances in intravenous thrombolysis and endovascular thrombectomy, nearly half of patients with acute ischemic stroke fail to achieve functional recovery even after technically successful recanalization. The recanalization-reperfusion gap—the discordance between angiographic vessel opening and tissue-level perfusion recovery—has brought thromboinflammation, the pathological interplay of coagulation and innate immunity, to the forefront of stroke biology. Neutrophil extracellular traps, platelet-leukocyte aggregates, complement activation, and vessel wall inflammation render clots resistant to lysis, promote microvascular obstruction and the no-reflow phenomenon, and amplify ischemia-reperfusion injury.

The surface of oxygenator membranes activate coagulation posing serious risks of thrombosis and stroke. These and many more examples have in common that the ...

Integrating human factors into post-market surveillance represents a critical evolution in medical device safety management. While premarket usability studies establish baseline performance, real-world use generates insights that traditional surveillance mechanisms often miss. Both EU MDR and FDA regulations increasingly emphasize continuous demonstration of device usability and safety throughout product lifecycles. By incorporating human factors methodology into post-market surveillance activities, manufacturers can identify user interaction issues, understand root causes of problems, and proactively address safety risks. This integration strengthens regulatory compliance, reduces costly recalls and corrective actions, and ultimately delivers safer, more user-friendly devices that better serve clinical needs in practice.  

The LATE-MT randomized controlled trial demonstrates that mechanical thrombectomy can improve 90-day functional outcomes in anterior-circulation large vessel occlusion stroke patients presenting 24 to 72 hours after symptom onset, compared to standard medical care. However, the procedure carries significant risks, including increased mortality rates and symptomatic intracranial hemorrhage. While thrombectomy's benefits within earlier time windows have been well established, extending treatment beyond 24 hours shows promise for patients with slower disease progression. Despite functional improvements, clinicians must carefully weigh the therapeutic advantages against elevated adverse event rates when considering late thrombectomy interventions. These findings from the prospective, multicenter trial were presented at the 2026 European Stroke Organisation Conference, providing critical evidence for decision-making in extended-window stroke treatment protocols.

Ischemic stroke remains a significant cause of mortality and disability worldwide, with conventional interventions constrained by limited therapeutic windows and blood-brain barrier penetration challenges. This comprehensive review examines nanotechnology's potential across four critical stroke management stages: prevention, neuroprotection, revascularization, and adjunctive therapy. The authors emphasize the value of staged nanomedicine interventions, from controlled drug delivery during prevention to extending acute treatment windows and enhancing therapeutic efficacy. By systematically addressing challenges at each management stage, nanotherapeutics offer promising solutions to overcome limitations of traditional thrombolysis and mechanical thrombectomy approaches, potentially improving patient outcomes and reducing long-term disability associated with ischemic stroke.

Phosphorylcholine coating represents a biomimetic surface treatment that replicates the outer membrane structure of human cells, offering significant advantages for medical device applications. This innovative coating technology substantially enhances biocompatibility while reducing adverse biological reactions. Key benefits include enhanced hemocompatibility through minimized platelet adhesion and reduced thrombosis risk, a diminished inflammatory response by suppressing immune cell activation, and exceptional long-term stability under physiological conditions through covalent bonding. These properties make phosphorylcholine-coated devices particularly valuable for blood-contacting applications and implantable medical systems, where biocompatibility and durability are critical for optimal clinical outcomes.

This article reviews contemporary strategies and mechanisms for developing medical anticoagulation coatings applied to blood-contacting devices. Medical polymers, valued for their thermal resistance, corrosion resistance, and flexibility, serve as foundational materials for cardiovascular stents, hemodialysis membranes, and catheters. However, thrombus formation on device surfaces remains a significant clinical challenge. The research systematically examines advanced approaches to construct anticoagulant surface coatings, addressing a critical need in biomaterials science. These innovations aim to enhance the biocompatibility and safety of implanted medical devices by preventing unwanted blood clotting, ultimately improving patient outcomes in cardiovascular and therapeutic applications.

Flow-diverting stents (FDs) for the treatment of cerebrovascular aneurysms are revolutionary. However, these devices require systemic dual antiplatelet therapy (DAPT) to reduce thromboembolic complications. Given the risk of ischemic complications as well as morbidity and contraindications associated with DAPT, demonstrating safety and efficacy for FDs either without DAPT or reducing the duration of DAPT is a priority. The former may be achieved by surface modifications that decrease device thrombogenicity, and the latter by using coatings that expedite endothelial growth. Biomimetics, commonly achieved by grafting hydrophilic and non-interacting polymers to surfaces, can mask the device surface with nature-derived coatings from circulating factors that normally activate coagulation and inflammation.

Endovascular thrombectomy (EVT) has emerged as an effective treatment option. Unfortunately, interfacility transfers to thrombectomy-capable centers often delay treatment time. The direct to angio suite (DTA) pathway reduces interfacility transfer time by foregoing the emergency department at the thrombectomy-capable center and directing patients immediately to the angio suite. Up to 22% of patients transferred under the DTA pathway will not have a large vessel occlusion on cerebral angiography or will experience significant neurological improvement, obviating the need for EVT. This study evaluated predictive factors associated with EVT under the DTA protocol.

Endothelialization, the formation of endothelial cell layers on blood-contacting medical devices, is critical for vascular implants such as stents and grafts. This biological response creates a natural, non-thrombogenic interface that enhances device performance and biocompatibility. Alta Biomed's PzF thin-film coating technology offers a promising surface modification strategy to optimize endothelialization while addressing concerns regarding thrombus formation, vascular healing, and coating integrity. Multiple factors influence endothelialization success, including device material, surface chemistry, coating selection, geometry, and local flow conditions. Strategic consideration of these elements during device development is essential for improving clinical outcomes.

The benefit of IV thrombolysis (IVT) before thrombectomy in patients with anterior-circulation large-vessel occlusion (LVO) due to carotid artery dissection (CAD) remains uncertain. We aimed to evaluate the safety and efficacy of IVT in this specific population in clinical practice.

Bioresorbable materials represent a rapidly advancing class of biomaterials designed to perform therapeutic or diagnostic functions before safely degrading into physiologically compatible products within the body. Unlike permanent implants, these materials eliminate the need for secondary surgical removal procedures, thereby reducing patient risk, healthcare costs, and long-term complications from foreign material retention. However, designing effective bioresorbable materials presents significant challenges, requiring materials to maintain mechanical stability during their functional lifetime while demonstrating predictable and controllable degradation patterns. Recent advances in materials science, nanotechnology, and biomedical engineering continue to address these complex requirements, promising to substantially enhance the safety and functionality of medical devices across numerous clinical applications.

Multifunctional implantable hydrogels represent a significant advancement in biomedical innovation, serving as intelligent platforms for diverse clinical applications. These sophisticated biomaterials integrate multiple functionalities within a single construct, enabling controlled drug delivery, tissue engineering, and biosensing capabilities. Their smart design allows for responsive behavior to environmental stimuli, enhancing therapeutic efficacy while minimizing adverse effects. This emerging technology demonstrates considerable potential in regenerative medicine and personalized treatment approaches, positioning hydrogels as transformative tools in modern healthcare delivery and disease management strategies.